VITAS Raises 2026 Earnings Guidance to $24.00 to $24.75 per Share
Consensus $23.88. The company said, "Historically, we do not give quarterly updates to guidance. Due to the materially improved performance of VITAS, coupled with the level of share repurchases in the first quarter of 2026, we believe updating guidance is appropriate in this instance. Further operational detail will be provided during the investor conference call. VITAS' initiatives to return to a normal growth pattern after managing the 2025 Medicare Cap issue were more quickly successful than originally anticipated. This led to higher revenue, excluding the impact of Medicare Cap, and adjusted EBITDA margins, excluding the impact of Medicare Cap, in the first quarter 2026 than what was included in the original guidance. As a result, anticipated ADC growth for 2026 is updated to a revised range of 4.5% to 5.5% compared to the original guidance range of 3.5% to 4.0%. Anticipated revenue growth, excluding the impact of the Medicare Cap, improves from the original guidance range of 5.5% to 6.5% to a revised range of 6.5% to 7.5%. Finally, revised EBITDA margin, excluding the impact of the Medicare Cap, is anticipated to be 18.0% to 18.5% compared to the original guidance of 17.5% to 18.5%. Roto-Rooter performed generally within our expectations. In total, there were various headwinds and tailwinds that contributed to the overall results in the first quarter of 2026. In the first quarter of 2026, unusual ice and snowstorms led to some level of service disruption for five days of the quarter across 24 Roto-Rooter branches. This resulted in an estimated loss of net revenue of between $3 million and $4 million in the quarter. Additionally, total leads for Roto-Rooter increased 3.3% during the quarter but continuing the previously discussed trends, a larger portion of those leads were the result of paid internet marketing. As a result, total marketing expense during the quarter exceeded our expectations by approximately $2.0 million. When factoring all the gives and takes within the expected Roto-Rooter performance for the remainder of fiscal 2026, anticipated revenue growth remains unchanged at 3.0% to 3.5%. Estimated adjusted EBITDA margin is lowered slightly to 21.5% to 22.5% compared to the original guidance range of 22.5% to 23.0%. This is primarily due to elevated marketing costs now expected to persist above our original guidance for the remainder of the year. Based on the above, full-year 2026 earnings per diluted share, excluding non-cash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $24.00 to $24.75. The mid-point of the revised guidance represents a 13% increase from 2025 adjusted earnings per diluted share of $21.55. The revised 2026 guidance assumes an effective corporate tax rate on adjusted earnings of 24.5% and a diluted share count of 13.6 million shares. The original 2026 guidance was for adjusted earnings per diluted share to be between $23.25 and $24.25."
Trade with 70% Backtested Accuracy
Analyst Views on CHE
About CHE
About the author

- Acquisition Deal: Chemed Corporation has acquired a formerly independent Roto-Rooter franchise for approximately $12 million, covering 21 counties in South Texas, including cities like Corpus Christi, McAllen, Laredo, and Brownsville, thereby expanding its market presence.
- Market Leadership: This acquisition is expected to enhance Chemed's service capabilities in Texas, as Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services, which may improve the company's overall business performance and customer base.
- Strategic Implications: By integrating this franchise, Chemed aims to optimize resource allocation and enhance service efficiency, thereby maintaining a competitive edge in a crowded market and meeting the growing customer demand.
- Future Outlook: Chemed's announcement includes caution regarding forward-looking statements, indicating that future performance may be influenced by various factors, urging investors to be aware of potential risks associated with these projections.
- Investor Stake Increase: Barington Capital has accumulated a stake in Chemed (CHE) and proposed former Cerberus Capital Management CEO Chan Galbato as a new board member, indicating confidence in the company's future prospects.
- Management Discussions: Barington has engaged in talks with Chemed's management regarding the potential addition of a new director, highlighting its focus on corporate governance and possibly prompting strategic adjustments within the company.
- Stock Price Reaction: Following the news, Chemed's stock rose by 2%, reflecting a positive market perception of Barington's involvement, despite a 27% decline in stock price over the past year.
- Dividend Declaration: Chemed declared a dividend of $0.60 per share, demonstrating the company's ability to maintain cash flow and shareholder returns in the current market environment.
- Dividend Declaration: Chemed has declared a quarterly dividend of $0.60 per share, consistent with previous payments, indicating the company's stable cash flow and profitability, which enhances investor confidence.
- Yield Metrics: The forward yield of 0.54% reflects the company's attractiveness in the current market environment, potentially drawing in more investors seeking stable income.
- Payment Schedule: The dividend is payable on June 16, with a record date of May 28 and an ex-dividend date also on May 28, ensuring shareholders receive their returns promptly, thereby reinforcing shareholder loyalty.
- Consistent Payout Record: Chemed has now announced a $0.60 dividend for four consecutive quarters, demonstrating the company's ongoing commitment to shareholder returns, which may enhance its market position within the healthcare sector.

- Board Election: At the 2026 annual meeting, Chemed Corporation's shareholders elected a slate of nine directors, ensuring stability in the governance structure and supporting future strategic decision-making.
- Auditor Reappointment: Shareholders unanimously ratified the continuation of PricewaterhouseCoopers as the independent accountants for 2026, reflecting a commitment to financial transparency and compliance, which enhances investor confidence.
- Shareholder Proposal Rejection: The non-binding proposal regarding executive compensation was not approved, indicating shareholder scrutiny over the company's executive pay policies, which may prompt a review and adjustment of compensation structures in the future.
- Quarterly Cash Dividend: The Board declared a cash dividend of 60 cents per share, payable on June 16, 2026, marking the 220th consecutive quarterly dividend, which underscores Chemed's consistent profitability and commitment to shareholder returns over its 55-year history.
- New Medicare Regulations: The U.S. government plans to temporarily block new home health and hospice providers from enrolling in Medicare on Wednesday, reflecting a stringent regulatory approach to combat fraud linked to government-backed healthcare programs.
- Nationwide Moratorium: This nationwide pause aims to address healthcare scams, particularly those affecting Medicare, and is expected to enhance transparency and compliance within the healthcare service sector.
- Anti-Fraud Task Force Actions: Vice President JD Vance's anti-fraud task force will announce several policy changes, emphasizing the crackdown on large-scale fraud, which aims to protect the interests of the American public and demonstrates a zero-tolerance stance towards healthcare fraud.
- Industry-Wide Impact: This move could significantly affect major home health and hospice providers, including BrightSpring Health Services and UnitedHealth, prompting companies within the industry to strengthen compliance measures in response to the new regulatory environment.
- Net Earnings Decline: Chemtrade Logistics Income Fund reported Q1 net earnings of C$25.4 million, a significant decrease of C$23.7 million year-over-year, primarily due to rising finance costs and unfavorable unrealized foreign exchange losses, indicating financial pressure on the company.
- Revenue Performance: The total revenue for Q1 reached C$503 million, showing growth compared to the previous year; however, this increase was insufficient to offset the rising costs, reflecting intensified market competition.
- Adjusted EBITDA Decrease: Adjusted EBITDA stood at C$113.5 million, down C$6.6 million or 5.5% year-over-year, highlighting challenges in profitability that may impact future investment decisions.
- Impact of Financial Costs: The significant impact of rising finance costs and foreign exchange losses on Chemtrade's financial condition raises concerns among investors regarding the company's future growth potential.







